Leukemia Research Reports最新文献_第3页

Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy 高危CLL罕见的中枢神经系统表现，对三联靶向治疗反应良好。

IF 0.8

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-06-12 DOI: 10.1016/j.lrr.2026.100597

Anusha Swaminathan, Shrinidhi Nathany, Surbhi Singh, Aastha Gupta, Ishita B Sen, Paritosh Garg, Aakriti kothari, Kanika Verma, Vikas Dua, Rahul Bhargava

{"title":"Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy","authors":"Anusha Swaminathan, Shrinidhi Nathany, Surbhi Singh, Aastha Gupta, Ishita B Sen, Paritosh Garg, Aakriti kothari, Kanika Verma, Vikas Dua, Rahul Bhargava","doi":"10.1016/j.lrr.2026.100597","DOIUrl":"10.1016/j.lrr.2026.100597","url":null,"abstract":"<div><div>Central nervous system (CNS) involvement in chronic lymphocytic leukemia (CLL) is rare and presents major diagnostic and therapeutic challenges. We report the case of a man in his late 40s with small lymphocytic leukemia, initially managed conservatively, who presented after four years with progressive left facial numbness, diplopia, and left oculomotor nerve palsy without B symptoms or raised intracranial pressure. He had high-risk disease biology with TP53 mutation and unmutated IGHV status. Positron emission tomography-computed tomography showed mildly FDG-avid systemic lymphadenopathy but intensely avid thickened spinal nerve roots, while magnetic resonance imaging demonstrated enhancement of the bilateral oculomotor nerves, left optic nerve, and extradural tissue at the cervical level. Cerebrospinal fluid analysis showed elevated protein and 34% abnormal B-lymphoid cells with a CLL phenotype. Biopsy of the involved nerve/root tissue confirmed direct CNS and nerve-root infiltration by CLL rather than Richter transformation. The patient was treated with acalabrutinib, venetoclax, obinutuzumab, and intrathecal chemotherapy. He showed rapid neurological improvement, with early symptom resolution, progressive cerebrospinal fluid clearance, and near-complete radiologic response, followed by complete metabolic response on follow-up PET-CT. This case highlights that CNS involvement may occur even in treatment-naïve or early-stage CLL and may not correlate with systemic disease burden. It also supports the clinical activity of novel triplet CNS-penetrant targeted agents, in achieving durable remission in rare CNS manifestations of high-risk CLL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100597"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13333278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report 暂时使用依鲁替尼后CLL/SLL的richter样转化：1例报告

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-03-02 DOI: 10.1016/j.lrr.2026.100578

Tung-Lin Chiang , John Frater , Amanda Cashen

引用次数: 0

Therapeutic outcomes of acute promyelocytic leukemia in children 儿童急性早幼粒细胞白血病的治疗效果

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-02-15 DOI: 10.1016/j.lrr.2026.100569

Sirine Chatti, Emna Azza, Marwa Bahri, Roua Hsasna, Yosr Ben Abdennebi, Lamia Aissaoui

引用次数: 0

Leukocytosis and a JAK2 mutation: The importance of expertise in somatic variant interpretation 白细胞增多症和JAK2突变：体细胞变异解释专业知识的重要性

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-01-13 DOI: 10.1016/j.lrr.2026.100563

Christian J. Puzo , Karl Hager , Michal Rose , Ellice Wong , Christopher A. Tormey , Alexa J. Siddon

引用次数: 0

The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia CDK4/6抑制剂和BRD4抑制剂在急性髓性白血病中的协同抑瘤作用

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2025-12-20 DOI: 10.1016/j.lrr.2025.100558

Kaiqiong Liao , Chong Guo , Min Zhang , Xiaobin Lv , Jinhua Yan

{"title":"The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia","authors":"Kaiqiong Liao , Chong Guo , Min Zhang , Xiaobin Lv , Jinhua Yan","doi":"10.1016/j.lrr.2025.100558","DOIUrl":"10.1016/j.lrr.2025.100558","url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this research is to explore the anti-leukemic properties of CDK4/6 inhibitors when used alongside BET inhibitors for treating acute myeloid leukemia (AML), as well as to clarify the molecular mechanisms involved.</div></div><div><h3>Methods</h3><div>Cell viability was assessed using the CCK-8 assay following treatment of AML cells with varying doses of SHR6390, a CDK4/6 inhibitor, and OTX015, a BET inhibitor.The time- and dose-dependent inhibitory effects of these two drugs on AML cells were assessed, and the respective IC50 and combination index (CI) values after co-treatment were calculated. The effects of SHR6390 and OTX015 on the growth potential of AML cells were additionally examined through soft agar colony formation assays and flow cytometry. Furthermore, RNA sequencing and Western blot analysis were conducted on cells treated with both drugs. The aim of this study is to explore the mechanism by which SHR6390 and OTX015 synergistically inhibit the proliferation of AML cells.The anti-tumor activity of SHR6390 and/or OTX015 in AML xenograft mice was also investigated through animal experiments.</div></div><div><h3>Results</h3><div>1. Either the CDK4/6 inhibitor SHR6390 or the BRD4 inhibitor OTX015, or a combination of the two, were employed to hinder both the survival and proliferation of cell lines associated with acute myeloid leukemia, showing a synergistic effect. 2. The combined application of SHR6390 and OTX015 markedly suppresses the invasive and migratory capacities of acute myeloid leukemia cells.3. The use of both SHR6390 and OTX015 induces apoptosis in acute myeloid leukemia cells while also disrupting cell cycle progression, leading to a halt before DNA replication occurs. 4. SHR6390 and OTX015 hinder the proliferation of acute myeloid leukemia cells by targeting both the PI3K-AKT-mTOR and the Wnt-β-Catenin pathway. 5. SHR6390 and OTX015 Synergistically Inhibit the Growth of AML Xenografts In Vivo.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100558"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecularly guided venetoclax duration in older adults with AML: Lessons from the OPTI-AML trial 分子引导venetoclax在老年AML患者中的持续时间：来自OPTI-AML试验的经验教训

IF 0.8

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-09-09 DOI: 10.1016/j.lrr.2026.100606

Jiandong Shi, Chunmeng Rong, Yiqin Weng

引用次数: 0

Mixed-phenotype acute leukemia: Flow cytometric analysis in a tertiary care center of Bangladesh 混合表型急性白血病：流式细胞术分析在孟加拉国三级保健中心。

IF 0.8

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-09-23 DOI: 10.1016/j.lrr.2026.100612

Shirin Tarafder, Sheikh Anisul Haque

{"title":"Mixed-phenotype acute leukemia: Flow cytometric analysis in a tertiary care center of Bangladesh","authors":"Shirin Tarafder, Sheikh Anisul Haque","doi":"10.1016/j.lrr.2026.100612","DOIUrl":"10.1016/j.lrr.2026.100612","url":null,"abstract":"<div><h3>Background</h3><div>Mixed-phenotype acute leukemia (MPAL) is a rare but difficult to treat hematologic malignancy.</div></div><div><h3>Methods</h3><div>flow cytometry immunophenotyping method was used in EDTA bone marrow and/or peripheral blood taken from all consecutive morphologically diagnosed acute leukemia (AL) patients from November 2015 to December 2019.</div></div><div><h3>Results</h3><div>Among 616 consecutive AL cases diagnosed and evaluated during this period, 22(3.57%) patients with MPAL were identified fulfilling WHO 2008 criteria for immunophenotypic characteristics of AL. Fifteen (68.2%) cases were diagnosed as B/myeloid, 5(22.72%) as T/myeloid and 2 (9.1%) as B/T MPAL. Morphologically diagnosed 15 (68.2%) AML cases were immunophenotypically B/Myeloid MPAL (12/15) and 3/15 cases were T/Myeloid MPAL. Morphologically 7 (31.8%) were ALL of which immunophenotypically 3/7 cases were B/Myeloid MPAL, 2/7 cases were T/Myeloid MPAL and 2/7 were B/T MPAL.</div></div><div><h3>Conclusion</h3><div>Multiparametric flow cytometry using comprehensive panel of monoclonal antibodies is a valuable tool to diagnose MPAL known to have a poor outcome.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"26 ","pages":"Article 100612"},"PeriodicalIF":0.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149116074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam 评估越南急性髓系白血病患者造血干细胞移植后降低强度调理方案的有效性

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-22 DOI: 10.1016/j.lrr.2026.100590

Man Van Huynh , Huu Than Huynh , Thu Hanh Nguyen , Tong Thanh Tran , Xuan Tuan Ma , Nam Duy Hoang , Chi Dung Phu

{"title":"Evaluating the effectiveness of reduced-intensity conditioning regimens in acute myeloid leukemia patients after hematopoietic stem cell transplantation in Vietnam","authors":"Man Van Huynh , Huu Than Huynh , Thu Hanh Nguyen , Tong Thanh Tran , Xuan Tuan Ma , Nam Duy Hoang , Chi Dung Phu","doi":"10.1016/j.lrr.2026.100590","DOIUrl":"10.1016/j.lrr.2026.100590","url":null,"abstract":"<div><h3>Objective</h3><div>Hematopoietic stem cell transplantation (HSCT) is an effective treatment for acute myeloid leukemia (AML) patients, leveraging cytotoxic conditioning regimens and graft-versus-leukemia effects. Reduced-intensity conditioning (RIC) regimens extend this therapy to elderly patients and those with severe comorbidities, minimizing toxicity while maintaining efficacy. The study aims to determine the result of reduced-intensity conditioning regimens for acute myeloid leukemia patients at Blood Transfusion Hematology Hospital, Vietnam.</div></div><div><h3>Methods</h3><div>The retrospective observational study included 21 AML patients who underwent RIC from January 2021 to March 2024.</div></div><div><h3>Results</h3><div>Median recovery times for neutropenia and thrombocytopenia were 16 and 26 days, respectively. Complications included mucositis (95.2%), febrile episodes (85.7%), CMV reactivation (83.3%), acute GVHD (23.8%), and chronic GVHD (14.3%). The 2-year disease-free survival (DFS) and overall survival (OS) rates were 61.4% and 69.3%, respectively.</div></div><div><h3>Conclusions</h3><div>Reduced-intensity conditioning regimens are a safe and effective treatment option for elderly AML patients with comorbidities.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100590"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147802512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune myelofibrosis with a TLR8 gain-of-function defect 自身免疫性骨髓纤维化伴TLR8功能获得缺陷

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-12 DOI: 10.1016/j.lrr.2026.100587

Shiqiang Qu , Peihong Zhang , Zefeng Xu , Tiejun Qin , Bing Li , Zhijian Xiao

引用次数: 0

Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML 靶向核苷酸代谢和表观遗传调控克服AML的分化阻断

IF 0.9

Leukemia Research Reports Pub Date : 2026-01-01 Epub Date: 2026-04-11 DOI: 10.1016/j.lrr.2026.100586

Shinichiro Takahashi

{"title":"Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML","authors":"Shinichiro Takahashi","doi":"10.1016/j.lrr.2026.100586","DOIUrl":"10.1016/j.lrr.2026.100586","url":null,"abstract":"<div><div>Differentiation blockade is a central pathogenic hallmark of acute myeloid leukemia (AML). While all-trans retinoic acid (ATRA) achieves curative differentiation in acute promyelocytic leukemia (APL), this success has not extended to other AML subtypes. Recently, inhibitors targeting nucleotide metabolism—such as cytarabine, dihydroorotate dehydrogenase (DHODH) inhibitors, and DNA hypomethylating agents—have emerged as promising candidates to overcome this therapeutic barrier. These compounds promote myeloid maturation through mechanisms involving cell-cycle arrest, epigenetic reprogramming, and replication stress–activated signaling. Preclinical and early clinical evidence suggests that targeting nucleotide metabolism may induce partial differentiation of leukemic blasts, providing a metabolic and epigenetic avenue for therapy beyond APL. This mini-review summarizes current understanding of how metabolic inhibition restores differentiation in AML, focusing on representative agents and their mechanistic and translational implications. Targeting de novo nucleotide biosynthesis may offer a metabolic and epigenetic route to expand differentiation-based strategies beyond APL.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"25 ","pages":"Article 100586"},"PeriodicalIF":0.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147709403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0